Researchers from Ben Gurion University of the Negev Report Findings in Schizophrenia (Curcumin as Add-On to Antipsychotic Treatment in Patients With Chronic Schizophrenia)
Middle East Daily
2019 AUG 15 (NewsRx) -- By a News Reporter-Staff News Editor at Middle East Daily -- Investigators discuss new findings in Mental Health Diseases and Conditions - Schizophrenia. According to news reporting originating in Beer Sheva, Israel, by NewsRx journalists, research stated, “Introduction of old and new generations of antipsychotics leads to significant improvements in the positive symptoms of schizophrenia. However, negative symptoms remain refractory to conventional trials of antipsychotic therapy.”
The news reporters obtained a quote from the research from the Ben Gurion University of the Negev, “Recently, there were several open clinical human trials with curcumin. Curcumin is a natural polyphenol, which has a variety of pharmacological activities, including antioxidative and neuroprotective effects. The studies showed that curcumin improved the negative symptoms of schizophrenia. The purpose of our study was to examine the efficacy of curcumin as an add-on agent to regular antipsychotic medications in patients with chronic schizophrenia. Thirty-eight patients with chronic schizophrenia were enrolled in a 24-week, double-blind, randomized, placebo-controlled study. The subjects were treated with either 3000 mg/d curcumin or placebo combined with antipsychotics from January 2015 to February 2017. The outcome measures were the Positive and Negative Symptoms Scale (PANSS) and the Calgary Depression Scale for Schizophrenia. Analysis of variance showed significant positive changes in both groups from baseline to the end of the study in all scales of measurement. There was a significant response to curcumin within 6 months in total PANSS (P = 0.02) and in the negative symptoms subscale (P = 0.04). There were no differences in the positive and general PANSS subscales, and the Calgary Depression Scale for Schizophrenia scores between the treatment and placebo groups. No patient complained of any adverse effect. The promising results of curcumin as an add-on to antipsychotics in the treatment of negative symptoms may open a new and safe therapeutic option for the management of schizophrenia.”
According to the news reporters, the research concluded: “However, these results should be replicated in further studies. Identifier: NCT 02298985.”
For more information on this research see: Curcumin as Add-On to Antipsychotic Treatment in Patients With Chronic Schizophrenia. Clinical Neuropharmacology, 2019;42(4):117-122. Clinical Neuropharmacology can be contacted at: Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA.
Our news correspondents report that additional information may be obtained by contacting V. Lerner, Ben-Gurion University of the Negev, Beer Sheva Mental Hlth Ctr, Faculty of Health Sciences, Beer Sheva, Israel. Additional authors for this research include C. Miodownik, N. Kudkaeva, Y. Bersudsky, R. Eliyahu, P.P. Lerner, A. Pashinian, A. Kreinin and J. Bergman.
The direct object identifier (DOI) for that additional information is: https://doi.org/10.1097/wnf.0000000000000344. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.
(Our reports deliver fact-based news of research and discoveries from around the world.)